In a few short years the San Diego Conference has become a leading forum on the use of nucleic acid probes and recombinant molecules for diagnostic and therapeutic We devised a versatile methodfor detectingnucleicacids in crude lysates of biologicalsamples. A controllednetworkof nucleicacid hybridscomposedof the targetfragment,several oligonucleotide probes,branchedDNA amplifiers, and labeled oligonucleotidesis producedon a solid phase to ultimately incorporate60 to 300 molecules of alkaline phosphatase, which are detected with a chemiiuminescent substrate.The visible lightoutputcan be recordedon a luminometeror on instantblack-and-whitefilm.Assayshave been developedfor the detection of Chiamydia trachomatis, Neissena gonorrhoeae, and for genes conferringpenicillinand tetracycline resistance.Conductedmuch like ELISAS, the assays are performedin about4 h (for 96 samples)in microtiterdishes.The moleculardetectionlimitof approximately50 000 moleculesof double-strandedDNA has permitted usto detectito 10 x 1o of C. trachomatis and N. gonorrhoeae with specific probe sequences.Bothplasmidand genomictarget sequencescan be detected by the same procedure.All of the assay compoChironCorporation,
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therapy represent the near-term impact of technology in modern health care.
The following group of papers deal with some of the topics covered at the 1988 San Diego Conference, which concentrated on "Practical Aspects of Molecular Probes." Building on the success of the first three conferences, the Fourth San Diego Conference-to be held October 25-27, 1989-will explore areas of genetic fingerprinting, oncogenes, viral and bacterial identification, automation and instrumentation, and anti-sense technology, thereby continuing the conference goal of providing a forum for new or innovative techniques in probe technology. Recently we have reported the development of a rapid method for the detection of nucleic acids in crude biological samples (1). First applied to the analysis of hepatitis B viral DNA in human serum and plasma, the method involves the solution-phase hybridization of several synthetic oligonucleotide probes to the target nucleic acid sequence in crude cellular lysates and the subsequent capture of the probetarget complex onto a solid phase. All steps in the analysis system (probe binding, solid-phase capture, amplified labeling) consist of specific nucleic acid hybridizations. An enzymatically generated chemiluminescent signal has been used for the final readout. Although polystyrene beads were used as the solid support for the hepatitis B studies, we have modified the system to utilize microtiter wells. With this adaptation, assays are conducted much like an EUSA (Figure 1) . One plate (96 samples) can be fully processed in 4 h.
Jonathan S. Rosenberg
Except for the solution-phase hybridization probes, which are unmodified synthetic oligonucleotides, all reagents, probes, components (including the microtiter
